Sökning: (WFRF:(Brazauskas Ruta))
> (2017) >
Long-Term Outcome o...
-
Cheng, Yee ChungMed Coll Wisconsin, Milwaukee, WI 53226 USA
(författare)
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
IVYSPRING INT PUBL,2017
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-328284
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-328284URI
-
https://doi.org/10.7150/jca.16870DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:135987915URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Introduction: Inflammatory breast cancer (IBC) is a rare aggressive form of breast cancer. It is well known that the long-term survival and progression-free survival of IBC are worse than that of non-IBC. We report the long term outcomes of patients with IBC and non-IBC who had undergone high-dose chemotherapy (HDC) with autologous hematopoietic cell transplantation (AHCT).Methods: All 3387 patients with IBC or non-IBC who underwent HDC with AHCT between1990-2002 and registered with CIBMTR were included in this analysis. Transplant-related mortality (TRM), disease relapse/progression, progression-free survival (PFS) and overall survival (OS) were compared between the two cohorts. Multivariate Cox regression model was used to determine the independent impact of stage on outcomes.Results: 527 patients with IBC and 2,860 patients with non-IBC were included; the median age at transplantation (47 vs 46 years old) and median follow-up period in the 2 groups (167 vs 168 months) were similar. The most common conditioning regimen was cyclophosphamide and carboplatin based in both groups (54% in IBC and 50% in non-IBC). AHCT was well tolerated in both groups. TRM was similar in both groups (one year TRM was 2% for IBC and 3% for non-IBC, p= 0.16). The most common cause of death was disease progression or relapse (81% in IBC and 75% in non-IBC). The median survival for both IBC and non-IBC was the same at 40 months. The PFS at 10 years was 27% (95% CI: 23-31%) for IBC and 24% (95% CI: 22-26%) for non-IBC (p= 0.21), and the OS at 10 years was 31% (95% CI: 27-35%) for IBC and 28% (95% CI: 26-30%) for non-IBC (p= 0.16). In univariate analysis, patients with stage III IBC and no active diseases at transplantation had lower PFS and OS than that in non-IBC. In multivariate analysis, controlling for age, disease status at AHCT, hormonal receptor status, time from HR 1.16, 95% CI: 1- 1.34, p=0.0459), worse PFS (HR: 1.17, 95% CI: 1.01-1.36, p= 0.0339) and higher risk of disease relapse/progression (HR: 1.24, 95% CI: 1.06- 1.45, p= 0.0082) as compared to stage III non-IBC. Amongst all patients a higher stage disease was associated with worse PFS, OS and disease relapse/ progression.Conclusions: Long-term outcomes of stage III IBC patients who underwent AHCT were poorer than that in non-IBC patients confirming that the poor prognosis of IBC even in the setting of HDC with AHCT.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Shi, YushuMed Coll Wisconsin, Milwaukee, WI 53226 USA.
(författare)
-
Zhang, Mei-JieMed Coll Wisconsin, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Milwaukee, WI 53226 USA.
(författare)
-
Brazauskas, RutaMed Coll Wisconsin, Milwaukee, WI 53226 USA.
(författare)
-
Hemmer, Michael T.Med Coll Wisconsin, Milwaukee, WI 53226 USA.
(författare)
-
Bishop, Michael R.Univ Chicago Hosp, Chicago, IL 60637 USA.
(författare)
-
Nieto, YagoUniv Texas, Houston, TX 77030 USA.
(författare)
-
Stadtmauer, EdwardUniv Penn, Philadelphia, PA 19104 USA.
(författare)
-
Ayash, LoisKarmanos Canc Inst, Detroit, MI USA.;Univ Minnesota, Minneapolis, MN 55455 USA.
(författare)
-
Gale, Robert PeterImperial Coll London, London, England.
(författare)
-
Lazarus, HillardUniv Hosp, Cleveland, OH USA.
(författare)
-
Holmberg, LeonaFred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
(författare)
-
Lill, MichaelCedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
(författare)
-
Olsson, RKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Stockholm, Sweden.(Swepub:uu)riols677
(författare)
-
Wirk, Baldeep MonaSeattle Canc Care Alliance, Seattle, WA USA.
(författare)
-
Arora, MuktaUniv Minnesota, Minneapolis, MN 55455 USA.
(författare)
-
Hari, ParameswaranMed Coll Wisconsin, Milwaukee, WI 53226 USA.
(författare)
-
Ueno, NaotoUniv Texas, Houston, TX 77030 USA.
(författare)
-
Med Coll Wisconsin, Milwaukee, WI 53226 USAMed Coll Wisconsin, Milwaukee, WI 53226 USA.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Cancer: IVYSPRING INT PUBL8:6, s. 1009-10171837-9664
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Cheng, Yee Chung
-
Shi, Yushu
-
Zhang, Mei-Jie
-
Brazauskas, Ruta
-
Hemmer, Michael ...
-
Bishop, Michael ...
-
visa fler...
-
Nieto, Yago
-
Stadtmauer, Edwa ...
-
Ayash, Lois
-
Gale, Robert Pet ...
-
Lazarus, Hillard
-
Holmberg, Leona
-
Lill, Michael
-
Olsson, R
-
Wirk, Baldeep Mo ...
-
Arora, Mukta
-
Hari, Parameswar ...
-
Ueno, Naoto
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Cance ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet